Merck has had an impressive run over the past six months as its shares have beaten the S&P 500 by 6.8%. The stock now trades ...

Merck’s analyst fair value estimate has shifted from US$124.88 to US$129.74 per share, providing an updated reference point ...

Exelixis EXEL announced a clinical development collaboration with pharma giant Merck & Co. MRK to evaluate its pipeline ...

Merck (MRK) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over the ...

In a report released today, from Jefferies maintained a Buy rating on Merck & Company, with a price target of $138.00. Meet Samuel – Your Personal Investing Prophet. Start a con ...

Merck (MRK) stock achieved a 5-day winning streak, with total gains during this time reaching 6.9%. The company’s market capitalization has jumped by approximately $17 billion over the past five days, ...

Merck & Co. Inc. (NYSE: MRK) on Friday agreed to acquire Cidara Therapeutics, Inc. (NASDAQ: CDTX) for $221.50 per share in cash, for a total transaction value of approximately $9.2 billion. “We ...

Merck (MRK)’s stock surged by 41% in the last six months, driven not only by a modest revenue increase but also by a significant profit jump and heightened investor confidence. The factors behind this ...